Home Newsfeeds JP Morgan Downgrades XP to Neutral, Announces $23 Price Target

JP Morgan Downgrades XP to Neutral, Announces $23 Price Target

JP Morgan analyst Domingos Falavina downgrades XP (NASDAQ:XP) from Overweight to Neutral and announces $23 price target.

byBenzinga Newsdesk

August 11, 2022

1 minute read

JP Morgan analyst Domingos Falavina downgrades XP (NASDAQ:XP) from Overweight to Neutral and announces $23 price target.

Exane BNP Paribas Downgrades Best Buy Co to Neutral

By Benzinga Newsdesk

January 12, 8:48 AM

Exane BNP Paribas analyst Chris Bottiglieri downgrades Best Buy Co (NYSE:BBY) from Outperform to Neutral.

BBY

Weed-Infused Fine Dining In Canada, Former Pot Prisoners Open Shop In NYC & More

By Jelena Martinovic

October 23, 9:21 AM

Cannabis-Infused Fine Dining Come To Downtown Edmonton Cannasseurs living in downtown Edmonton, Alberta, could soon enjoy cannabis-infused meals and mocktails at a local restaurant, reported CBC.

CSE:TRUL

Adamis Pharmaceuticals Provides Update On Clinical Study Assessing Tempol For The Treatment Of COVID-19

By Benzinga Newsdesk

July 29, 7:31 AM

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today provided an update on the Company's ongoing U.S. Phase 2/3 clinical trial to evaluate the safety and efficacy of Tempol as a treatment for COVID-19. The

ADMP